Ultragenyx Pharmaceutical (RARE) Gains from Investment Securities (2013 - 2014)
Ultragenyx Pharmaceutical (RARE) posted quarterly Gains from Investment Securities of $3.3 million for Q1 2014, up 166300.0% year-over-year from N/an in Q1 2013, and up 82.34% quarter-over-quarter from $1.8 million in Q4 2013.
Powered by 
Analysis
Ultragenyx Pharmaceutical (RARE) Gains from Investment Securities (2013 - 2014) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Gains from Investment Securities for 2 consecutive years, with $3.3 million the latest figure, recorded in Q1 2014.
- In Q1 2014, Gains from Investment Securities rose 166300.0% year-over-year to $3.3 million; the TTM figure through Dec 2014 stood at $3.3 million (up 14.58% YoY), while the FY2014 annual figure was $3.3 million, up 14.58% from the prior year.
- Gains from Investment Securities rose to $3.3 million in Q1 2014 per RARE's latest filing, from $1.8 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $3.3 million in Q1 2014 and bottomed at -$2000.0 in Q1 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Ultragenyx Pharmaceutical | 1.56 Bn | 1.27 Bn | 180.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2014 | 3.32 Mn |
| Dec 31, 2013 | 1.82 Mn |
| Sep 30, 2013 | 706,000.00 |
| Jun 30, 2013 | 374,000.00 |
| Mar 31, 2013 | -2,000.00 |